From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement
作者:Yelena Mostinski、Guus J. J. E. Heynen、Maria Pascual López-Alberca、Jerome Paul、Sandra Miksche、Silke Radetzki、David Schaller、Elena Shanina、Carola Seyffarth、Yuliya Kolomeets、Nandor Ziebart、Judith de Schryver、Sylvia Oestreich、Martin Neuenschwander、Yvette Roske、Udo Heinemann、Christoph Rademacher、Andrea Volkamer、Jens Peter von Kries、Walter Birchmeier、Marc Nazaré
DOI:10.1021/acs.jmedchem.0c01265
日期:2020.12.10
SHP2 inhibitors. We applied scaffold hopping and bioisosteric replacement concepts to eliminate unwanted structural motifs and to improve the inhibitor characteristics of the previously reported pyrazolone SHP2 inhibitors. The most potent azaindole 45 inhibits SHP2 with an IC50 = 0.031 μM in an enzymatic assay and with an IC50 = 2.6 μM in human pancreas cells (HPAF-II). Evaluation in a series of cellular
highly effective for one DBTO disulfonic acid derivative (>99% pure). The direct approach was the most straightforward and highest-yielding route. Additionally, a highly effective, scalable, and improved purification method was identified for disulfonic acid DBT and DBTO derivatives, allowing for the isolation of positional isomers and other modifications by using reverse-phase high-performance flash chromatography